UNLIMITED TURBO LONG - NOVO-NORDISK B | Market Closed - Deutsche Boerse AG 15:21:06 14/06/2024 BST | ||
| 14.19 EUR | +1.72% |
|
| Current month | +12.98% | ||
| 1 month | +17.47% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 14.19 | +1.72% |
| 13/06/24 | 13.95 | -1.41% |
| 12/06/24 | 14.15 | +1.14% |
| 11/06/24 | 13.99 | -0.50% |
| 10/06/24 | 14.06 | +0.07% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 03:21 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WKN | PE8GAV |
| ISIN | DE000PE8GAV2 |
| Date issued | 31/01/2023 |
| Strike | 467.2 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 1.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.27 € |
|---|---|
| Lowest since issue | 0.72 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
991
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.72%
- Stock Market
- Certificates
- Certificat